{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:43:05Z","timestamp":1758606185222,"version":"3.44.0"},"reference-count":55,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009287","name":"NSW Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Sociology Health &amp;amp; Illness"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In 2020, there were reports that HIV antiretrovirals, specifically the combination tenofovir disoproxil fumarate and emtricitabine (TDF\/FTC), had therapeutic potential for COVID\u201019. In the context of scant empirical evidence at the time to confirm such an effect, we sought to understand the ways that gay and bisexual men (GBM) made sense of\u2014and embodied\u2014information about HIV antiretrovirals in relation to preventing and\/or treating COVID\u201019. We conducted interviews with 26 participants between August and November 2020. To understand how information about, and experiences of, consuming antiretrovirals might form part of assemblages of COVID\u201019 prevention for GBM in Australia, we draw on Marsha Rosengarten's (2009) concept of \u2018informed matter\u2019. \u2018Informed matter\u2019 conceptualises the subject (of disease prevention) as involved in a co\u2010constitutive relationship with the contextual dynamics in which it is situated. Participants drew on their understandings of virology, immunology and pharmaceuticals and experiences with antiretrovirals to form perceptions about their function as therapeutics for COVID\u201019. By looking beyond biotechnologies as causal of behaviour, we can avoid unintended moralism in contexts of potentially different use. We argue that using \u2018informed matter\u2019 is useful to interrogate, often neglected, complex changes in sex\u2010associated biotechnologies in complicated informational contexts, such as a global pandemic.<\/jats:p>","DOI":"10.1111\/1467-9566.70078","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T13:05:25Z","timestamp":1755954325000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The \u2018Informed Matter\u2019 of Gay and Bisexual Men's (Potential) Use of HIV Antiretrovirals to Prevent COVID\u201019"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-7664","authenticated-orcid":false,"given":"Daniel","family":"Storer","sequence":"first","affiliation":[{"name":"School of Population Health UNSW Sydney  Sydney Australia"},{"name":"School of Law Society and Criminology UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-7091","authenticated-orcid":false,"given":"Dean","family":"Murphy","sequence":"additional","affiliation":[{"name":"School of Population Health UNSW Sydney  Sydney Australia"},{"name":"Australian Research Centre in Sex Health and Society La Trobe University  Melbourne Australia"},{"name":"School of Translational Medicine Monash University  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8105-1931","authenticated-orcid":false,"given":"Niamh","family":"Stephenson","sequence":"additional","affiliation":[{"name":"School of Population Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3917-8992","authenticated-orcid":false,"given":"Garrett","family":"Prestage","sequence":"additional","affiliation":[{"name":"Kirby Institute UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-7969","authenticated-orcid":false,"given":"Mohamed A.","family":"Hammoud","sequence":"additional","affiliation":[{"name":"Kirby Institute UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"volume-title":"Post\u2010Exposure Prophylaxis After Non\u2010Occupational and Occupational Exposure to HIV: Australian National Guidelines","year":"2023","author":"ASHM","key":"e_1_2_13_2_1"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa455"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0263276405048433"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.08.005"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/2159676x.2019.1628806"},{"volume-title":"Annual Report of Trends in Behaviour 2024: Viral Hepatitis, HIV, STIs and Sexual Health in Australia","year":"2024","author":"Broady T.","key":"e_1_2_13_7_1"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2043820621989574"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002639"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18063266"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20\u20103689"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003372"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac188"},{"key":"e_1_2_13_15_1","unstructured":"Deleuze G. andF. l.Guattari.1988.A Thousand Plateaus: Capitalism and Schizophrenia. Translated by B. MassumiContinuum."},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.53854\/liim\u20102904\u20104"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00489"},{"key":"e_1_2_13_18_1","unstructured":"European Medicines Agency.2023.Truvada.European Medicines Agency.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/truvada#ema\u2010inpage\u2010item\u2010authorisation\u2010details."},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820002253"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/nup.12136"},{"key":"e_1_2_13_21_1","unstructured":"Gilead.2008.U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults.Gilead.https:\/\/www.gilead.com\/news\/news\u2010details\/2008\/us\u2010food\u2010and\u2010drug\u2010administration\u2010approves\u2010vireadr\u2010for\u2010chronic\u2010hepatitis\u2010b\u2010in\u2010adults."},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10304312.2021.1992350"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002462"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/09581596.2013.796038"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13691058.2014.960003"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010022\u201003603\u2010x"},{"volume-title":"PrEP Manufacturer to Test Drug Against COVID\u201019\u2014But Has Low Expectations","year":"2020","author":"Johnson C.","key":"e_1_2_13_28_1"},{"volume-title":"PrEP May Be Tested Against Coronavirus if Antivirals Shown to Work","year":"2020","author":"Johnson C.","key":"e_1_2_13_29_1"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000234085.18914.d5"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033119"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1332\/174426420X15913559981103"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13515"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1357034x241298173"},{"issue":"9","key":"e_1_2_13_35_1","first-page":"1","article-title":"Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis","volume":"54","author":"Panlilio A. L.","year":"2005","journal-title":"Morbidity and Mortality Weekly Report Recommendations and Reports"},{"key":"e_1_2_13_36_1","unstructured":"PBS.2009.Tenofovir Disoproxil Fumarate Tablet 300 Mg Viread\u00ae November 2008.Department of Health Disability and Ageing.https:\/\/m.pbs.gov.au\/industry\/listing\/elements\/pbac\u2010meetings\/psd\/2008\u201011\/pbac\u2010psd\u2010tenofovir\u2010nov08.html."},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010022\u201003611\u2010x"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1363460714550913"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans\u20102020\u2010054756"},{"volume-title":"HIV Interventions: Biomedicine and the Traffic Between Information and Flesh","year":"2009","author":"Rosengarten M.","key":"e_1_2_13_40_1"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2009.07.039"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/09505430902885565"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467\u20109566.13502"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467\u20109566.13687"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1590\/0102\u2010311X00202420"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/00918369.2016.1158012"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010021\u201085359\u20103"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010020\u201002984\u20101"},{"key":"e_1_2_13_49_1","unstructured":"U.S. Food and Drug Administration.2001.Drug Approval Package: VIREAD (Tenofovir Disoproxil Fumarate) Tablets.U.S. Department of Health and Human Services.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21\u2010356_Viread.cfm."},{"key":"e_1_2_13_50_1","unstructured":"U.S. Food and Drug Administration.2003.Drug Approval Package: Emtriva (Emtricitabine) 200 Mg Tablets.U.S. Department of Health and Human Services.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/021500_emtriva_toc.cfm."},{"key":"e_1_2_13_51_1","unstructured":"U.S. Food and Drug Administration.2006.Drug Approval Package: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) Tablets.U.S. Department of Health and Human Services.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/021752s000_TruvadaTOC.cfm."},{"key":"e_1_2_13_52_1","unstructured":"U.S. Food and Drug Administration.2016.Drug Approval Package: Descovy (Emtricitabine\/Tenofovir Alafenamide).U.S. Department of\u00a0Health and Human Services.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208215Orig1_toc.cfm."},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000003577"},{"key":"e_1_2_13_54_1","first-page":"165","article-title":"Les Personnes Seropositives ne Souffrant d\u2019aucune Autre MST et Suivant un Traitement Antiretroviral Efficace ne Transmettent pas le VIH par voie Sexuelle","volume":"81","author":"Vernazza P.","year":"2008","journal-title":"Bulletin des Medecins Suisses"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467\u20109566.13632"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31827e854a"}],"container-title":["Sociology of Health &amp; Illness"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1467-9566.70078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:39:21Z","timestamp":1758602361000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1467-9566.70078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/1467-9566.70078"],"URL":"https:\/\/doi.org\/10.1111\/1467-9566.70078","archive":["Portico"],"relation":{},"ISSN":["0141-9889","1467-9566"],"issn-type":[{"type":"print","value":"0141-9889"},{"type":"electronic","value":"1467-9566"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"2024-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70078"}}